Quoin pharmaceuticals launches ‘netherton now' campaign to raise awareness of netherton syndrome, a rare genetic disease with no approved treatment or cure

Ashburn, va., feb. 04, 2025 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, has launched the “netherton now” campaign to shed light on the profound and poorly understood impacts of netherton syndrome, a devastating genetic disease that has been significantly misdiagnosed in the past. it is estimated that up to 20% of babies born with netherton syndrome do not survive, highlighting the urgent need for greater awareness and new treatment options.
QNRX Ratings Summary
QNRX Quant Ranking